Arcutis Biotherapeutics I... (ARQT)

The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question...

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frank Watanabe - Corporate Participant Latha Vairavan - Corporate Participa...

Arcutis (ARQT) Q2 Revenue Soars 164%

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.42 per share a year ago.

Upgrading Arcutis Biotherapeutics, Inc. from Hold to Buy due to Zoryve's strong regulatory and commercial momentum, with revenue and prescription growth exceeding expectations. Zoryve's expanding labe...

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shif...

Shares of Arcutis Biotherapeutics have fallen by 5% since my March update. Zoryve's 4th approval in scalp & body psoriasis should further boost sales and contribute to the "portfolio effect". IP devel...

Arcutis Biotherapeutics stands out in biotech for its impressive factor grades, which are rare in this sector. The recent FDA approval of ZORYVE Topical foam opens a significant revenue and profitabil...